🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526884-39-00
Authorised Phase III

Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)

2026-526884-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Hospitalier Universitaire De Toulouse
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Nervous System Diseases
Decision date
01/09/2026
Enrollment target
12
Sites
France

Condition studied

Stroke

Investigational medicinal product(s)

LIORÉSAL 10 mgcomprimé sécableNEURONTIN 100 mggéluleNEURONTIN 300 mggéluleNEURONTIN 400 mggéluleSERESTA 10 mgcomprimé

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Variation (Δ) in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between pre-PAS and post-PAS measurements, assessed at each session

Endpoint detail

Cortical excitability (TMS): resting motor threshold, MEP amplitude and latency, assessed at each session., Motor learning performance: learning effect, rebound, and retention on SRTT and Target Jump tasks, assessed at each session., Safety: spontaneous report on adverse events, assessed at each session, Severity of the symptom that led to treatment prescription reported by the patient using the Patient Global Impression of Severity (PGI-S)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526884-39-00 on CTIS ↗ ← All trials in the EU